At a Glance
- Company: TRexBio Inc.
- Location: South San Francisco, California
- Headline figures: $50m Series B extension (oversubscribed)
- Focus area: Treg-targeted therapies for atopic dermatitis
- Next steps: TRB-061 phase 1b data 2027; TRB-071/081 phase 1 2027
What happened?
TRexBio announced an oversubscribed $50 million extension to its Series B financing on 27 January 2026, bringing new investors Janus Henderson, Balyasny and Affinity alongside Eli Lilly, J&J Innovation, Pfizer Ventures and others. Funds advance TRB-061, a TNFR2 agonist activating tissue-resident regulatory T cells (Tregs), currently in phase 1a/b for moderate-to-severe atopic dermatitis.
Why does it matter?
Atopic dermatitis affects 20m+ US adults; current biologics broadly suppress immunity while TNFR2-selective Treg activation offers precision control of skin inflammation without systemic risks. TRexBio’s Deep Biology Platform derives candidates from human tissue Treg data, addressing unmet needs in barrier-tissue diseases.
Who’s behind it?
TRexBio develops immunoregulatory therapies from proprietary Treg biology platform; prior $84m Series B (2024) funded TRB-061 phase 1 initiation plus Lilly/J&J partnerships.
How was it achieved?
TRB-061 mimics natural TNF ligand to stimulate suppressive skin/gut Tregs via TNFR2, confirmed safe in phase 1a single-dose; multiple-ascending dose ongoing with 2027 readout. Platform generated pipeline including wholly-owned TRB-071/TRB-081 for inflammation/autoimmunity.
What’s next?
Complete TRB-061 phase 1b atopic dermatitis; initiate phase 1 for TRB-071/TRB-081 in 2027 targeting inflammatory diseases. Funds extend runway into clinical readouts.
What are people saying?
CEO Johnston Erwin: “TRB-061… designed to apply decades of insight into Treg-mediated immune regulation toward a more precise treatment approach.”